<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124850</url>
  </required_header>
  <id_info>
    <org_study_id>VRXP-A106</org_study_id>
    <nct_id>NCT02124850</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab</brief_title>
  <official_title>A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VentiRx Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VentiRx Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol VRXP-A106 will enroll patients with Stage II-IVA head and neck cancer patients who
      will be treated with surgical resection. Cetuximab and motolimod (Cohort 1); and cetuximab,
      motolimod, and nivolumab (Cohort 2) will be administered for a 3-4 week period before
      surgery. The primary objective of the study is to determine the extent to which the
      administration of neoadjuvant motolimod plus cetuximab and motolimod plus cetuximab and
      nivolumab modulates immune biomarkers (NK, mDC and T cell activation as well as tumor
      infiltration and serum cytokines) in peripheral blood and head and neck cancer tumors. An
      exploratory objective of the study is to assess whether modulation of biomarkers as described
      above can predict anti-tumor response.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in immune biomarkers including FcγR genotype, NK activation, tumor infiltration and serum cytokines, mDC, T cell activation, and tumor-antigen specific cytotoxic T lymphocyte induction.</measure>
    <time_frame>change from baseline to up to 4 weeks</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Anti-tumor response</measure>
    <time_frame>Change from baseline to pre-surgery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: motolimod plus cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: motolimod, cetuximab, and nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motolimod</intervention_name>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>VTX-2337</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Motolimod plus cetuximab</arm_group_label>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Motolimod, cetuximab, and nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated stage II, III, or IVA histologically or cytologically confirmed
             squamous cell carcinoma of the head and neck

          -  Primary tumors of the oral cavity, oropharynx, hypopharynx, or larynx

          -  Macroscopic complete resection of the primary tumor must be planned

          -  Age ≥ 18 years

          -  ECOG performance status 0-1

          -  Adequate hematologic, renal and hepatic function

          -  Have signed written informed consent

        Exclusion Criteria:

          -  Subjects who fail to meet inclusion criteria

          -  Primary tumors of the sinuses, paranasal sinuses, or nasopharynx, or unknown primary
             tumors

          -  Prior severe infusion reaction to a monoclonal antibody

          -  Pregnancy or breastfeeding

          -  Evidence of distant metastasis

          -  Any other malignancy active within 5 years except for non-melanoma skin cancer or
             carcinoma in situ of the cervix, DCIS or LCIS of the breast

          -  Prior history of head and neck cancer

          -  Prior therapy with motolimod, nivolumab, or other agents targeting PD-1/PD-L1

          -  Prior therapy targeting the EGFR pathway

          -  Acute hepatitis, known HIV, or active uncontrolled infection

          -  Patients with active autoimmune disease

          -  History of uncontrolled cardiac disease within prior 6 months

          -  Uncontrolled peptic or gastric ulcer disease, or gastrointestinal bleeding within
             prior 6 months

          -  Active alcohol abuse or other illness or circumstance that carries a likelihood of
             inability to comply with study treatment and follow-up or otherwise compromise the
             study's objectives

          -  Treatment with a non-approved or investigational drug within 30 days prior to Day 1 of
             study treatment

          -  Live vaccine within 30 days of planned start of study therapy

          -  History of pneumonitis or interstitial lung disease

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to nivolumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ferris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanyu Song</last_name>
    <phone>(206) 973-1571</phone>
    <email>ysong@ventirx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Muniz</last_name>
      <phone>412-623-6121</phone>
      <email>munizca@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Ferris, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 17, 2017</submitted>
    <returned>March 7, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

